News

Horizon’s TEPEZZA® (teprotumumab-trbw) treatment will be produced from AGC Biologics’ new facility in Boulder, CO

(SEATTLE), October 29, 2020 -- AGC Biologics, a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced that its partnership with Horizon Therapeutics plc (Nasdaq: HZNP) is expanding to produce Horizon’s Thyroid Eye Disease (TED) treatment, TEPEZZA, at AGC’s new facility in Boulder, CO. The state-of-the-art facility includes two 20,000L stainless steel mammalian bioreactors which AGC is offering to customers who need very high-volume commercial production.

AGC Biologics Now Provides End-to-End Cell and Gene Therapy CDMO Services

(SEATTLE), October 27, 2020 -- After its parent company AGC Inc. acquired 100% of the shares of MolMed S.p.A. on September 30, 2020, AGC Biologics announced that MolMed’s entity name has been changed to AGC Biologics S.p.A. This Center of Excellence for AGC Biologics’ cell and gene therapy Contract Development and Manufacturing Organization (CDMO) services is in Milan, Italy. The Milan site was the first GMP facility approved in Europe for ex-vivo gene therapy manufacturing and has unique commercial manufacturing experience, with two cell & gene therapy products. AGC Biologics is now one of the very few CDMO’s in the world offering both plasmid production and end-to-end cell and gene therapy services.

(SEATTLE, WA), October 15, 2020 – AGC Biologics, a leading global biopharmaceutical contract development and manufacturing organization (CDMO), has announced a leadership update at the United States and Copenhagen facilities. The changes are being made to strengthen the strategic development and executive oversight of the rapid growing facilities in the US and Copenhagen, and are effective at the date of release, October 15, 2020.

(SEATTLE, WA), October 12, 2020 – AGC Biologics, a leading global biopharmaceutical contract development and manufacturing organization (CDMO), has announced a new appointment to initiate integration efforts resulting from the July 31, 2020 acquisition of MolMed, a biotechnology company focused on research, development, production and clinical validation of cell and gene therapies for the treatment of cancer and rare diseases. Effective immediately, Luca Alberici will transition from Chief Business Officer of MolMed to take on the role of General Manager/Site Head at the Milan, Italy site.